Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Truncated LHRH formulations

A domain, lipopeptide technology applied in the field of truncated LHRH formulations

Inactive Publication Date: 2007-12-05
昆士兰医学研究所理事会(QIMR)
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It should be recognized that these types of epitopes may vary widely

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Truncated LHRH formulations
  • Truncated LHRH formulations
  • Truncated LHRH formulations

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] Each group of dogs received a total of 5n moles of a mixed peptide consisting of P25, P35 and P62 coupled to LHRH(2-10) as the first dose. As a second and third dose, one group of dogs received the same vaccine, while a second group received a vaccine consisting only of P25 coupled to LHRH(6-10). Dogs received three doses of the vaccine at 0, 4, and 14 weeks.

[0078] Vaccine preparation: 1 to 1.5 mg of each peptide was weighed and dissolved in 100 ul of 4M urea. Solutions corresponding to 1.7 nmoles of each peptide were mixed and diluted with isotonic saline to the prescribed dose volume for injection (1 ml per dose). Add 150ug of Iscomatrix to each dose  (CSL, Melbourne, Australia) as an adjuvant. The vaccine is given to the dog on the back of the neck.

[0079] The measured antibody titers are shown in Figure 1. Simultaneous testosterone and progesterone levels are shown in Figure 2 and Figure 3, respectively.

Embodiment 2

[0081] Vaccination regimen:

[0082] The Beagle / foxhounds were divided into three groups. One group (12 dogs) received three doses of 5n molar total peptide consisting of a mixture of p25, p35 and p62 peptides coupled to LHRH (6-10).

[0083] A second group (6 dogs) received three doses of 5n molar total peptide consisting of a mixture of p25, p35 and p62 peptides coupled to LHRH (2-10).

[0084] A third group (6 dogs) received three doses of 5n molar total peptide consisting of a mixture of p25, p35 and p62 peptides coupled to LHRH (2-10) as the first dose. For the second and third doses, the vaccine consisted of a mixture of the same peptides conjugated to LHRH(6-10).

[0085] Dogs received three doses of the vaccine at 0, 4, and 14 weeks.

[0086] vaccine preparation

[0087] Weigh 1 to 1.5 mg of each peptide and dissolve in 100 ul of 4M urea respectively. Solutions corresponding to 1.7 nmoles of each peptide were mixed and diluted with isotonic saline to the prescribe...

Embodiment 3

[0091] Vaccination regimen:

[0092]Divide the Beagles / Foxhounds into two groups. The first group (15 dogs) received three doses of 35n molar total peptide consisting of a mixture of p4, p10, p24, p25, p27, p35 and p62 peptides coupled to LHRH (6-10).

[0093] A second group (15 dogs) received three doses of 35n molar total peptide consisting of a mixture of p4, p10, p24, p25, p27, p35 and p62 peptides coupled to LHRH (4-10).

[0094] Dogs received three doses of the vaccine at 0, 4, and 14 weeks.

[0095] Vaccine preparation:

[0096] Weigh 1 to 1.5 mg of each peptide and dissolve in 100 ul of 4M urea respectively. Solutions corresponding to 5 nmoles of each peptide were mixed and diluted with isotonic saline to the prescribed dose volume for injection (1 ml per dose). Add 150ug of Iscomatrix to each dose  (CSL, Melbourne, Australia) as an adjuvant. The vaccine is given to the dog on the back of the neck.

[0097] The experimental results are shown in Figure 11 to Fig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a peptide useful for raising an antiLHRH response in an animal. The peptide comprises a first and second region, the first region consisting of a sequence of less than 60 amino acids which comprises at least one T helper cell epitope and the second region consisting of the sequence SYGLRPG.

Description

field of invention [0001] The present invention relates to peptides comprising truncated forms of LHRH and T helper epitopes. These formulations can be used to increase antibodies against LHRH in animals. Background of the invention [0002] Any peptide capable of inducing an effective antibody response must contain a specific sequence of amino acids, known as an epitope, that is recognized by the immune system. Especially during an antibody response, epitopes need to be recognized by specific immunoglobulin (Ig) receptors on the surface of B lymphocytes. These cells eventually differentiate into plasma cells, which are able to produce antibodies specific for this epitope. In addition to these B-cell epitopes, the immunogen must also contain epitopes that are presented by antigen-presenting cells (APCs) to specific receptors present on helper T lymphocytes, which are essential for the differentiation of B cells into antibody-producing cells. desired signal is required. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/59A61K38/24A61P15/16A61P15/18
CPCC07K14/59A61K39/0006C07K2319/00C07K7/08A61K38/00C07K7/23A61K2039/6018A61P15/16A61P15/18A61P5/10A61K38/24
Inventor 戴维·查尔斯·杰克逊约翰·沃克曾伟光
Owner 昆士兰医学研究所理事会(QIMR)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com